Dynavax Technologies Corporation (LON:0IDA)
10.29
+0.14 (1.41%)
At close: Oct 24, 2025
Dynavax Technologies Revenue
Dynavax Technologies had revenue of $95.44M USD in the quarter ending June 30, 2025, with 29.33% growth. This brings the company's revenue in the last twelve months to $316.27M, up 26.66% year-over-year. In the year 2024, Dynavax Technologies had annual revenue of $277.25M with 19.36% growth.
Revenue (ttm)
$316.27M
Revenue Growth
+26.66%
P/S Ratio
3.96
Revenue / Employee
$780.91K
Employees
405
Market Cap
914.90M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 277.25M | 44.96M | 19.36% |
| Dec 31, 2023 | 232.28M | -490.40M | -67.86% |
| Dec 31, 2022 | 722.68M | 283.24M | 64.45% |
| Dec 31, 2021 | 439.44M | 399.19M | 991.75% |
| Dec 31, 2020 | 40.25M | 5.03M | 14.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Dynavax Technologies News
- 27 days ago - 3 Of My Favorite Biotech Stocks Under $10 - Seeking Alpha
- 5 weeks ago - Dynavax Technologies Enters Oversold Territory (DVAX) - Nasdaq
- 2 months ago - Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference - PRNewsWire
- 2 months ago - Dynavax Says Investigational Shingles Vaccine At Par With GSK's Vaccine In Early-Stage Study - Benzinga
- 2 months ago - Dynavax says shingles shot performed on par with GSK’s Shingrix in Phase 1/2 trial - Seeking Alpha
- 2 months ago - Dynavax's shingles vaccine shows similar immune response to GSK's shot in study - Reuters
- 2 months ago - Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile - PRNewsWire
- 2 months ago - Dynavax Technologies: A Dip To Accumulate - Seeking Alpha